ACC Live Courses
For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings
- Conduction Abnormalities Requiring PPM Common After TAVR, State-of-the-Art Review FindsAs TAVR is increasingly used as an alternative to surgical aortic valve replacement (SAVR), conduction abnormalities, such as new onset left bundle branch block (LBBB) and high-grade atrioventricular block (AVB), requiring permanent pacemaker (PPM) implantation remain common following TAVR, according to a state-of-the-art review published Jan. 18 in JACC: Cardiovascular Interventions.
- Empagliflozin in Non-diabetic Heart Failure Patients With Reduced Ejection FractionThe goal of the EMPATROPISM trial was to evaluate empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, compared with placebo among non-diabetic patients with heart failure with reduced ejection fraction (HFrEF).
- Unplanned PCI After TAVRWhat is the incidence, timing, and cause of unplanned percutaneous coronary intervention (PCI) after transcatheter aortic valve replacement (TAVR)?
- Long-Term Beta-Blocker Use After MI in Patients Without HFAre beta-blockers cardioprotective among patients with stable, optimally treated myocardial infarction (MI) and no heart failure (HF)?
- Cerebral Protection Devices for TAVR PatientsWhat is the impact of cerebral protection devices on outcomes during transfemoral transcatheter aortic valve replacement (TAVR) in real-world clinical practice?